Citi lowered the firm’s price target on Kenvue (KVUE) to $20 from $22 and keeps a Neutral rating on the shares. The firm updated models in the beverages and home and personal care group. Citi favors ...

Kenvue's interim CEO Kirk Perry met Robert F. Kennedy Jr. to try and dissuade him from listing Tylenol as a potential cause ...

Kenvue interim CEO Kirk Perry met privately this week with RFK Jr. to argue that there is no proven link between Tylenol and ...

Despite Kenvue’s recent underperformance relative to the Dow, analysts remain moderately optimistic about the stock’s ...

Beyond oral care, Kenvue is aligning its strategy with the government’s Healthy China 2030 initiative, a national plan to ...

Tylenol-maker Kenvue Inc. spoke with Health Secretary Robert F. Kennedy Jr. in a bid to keep the over-the-counter painkiller ...

If you have been watching Kenvue (KVUE) lately, there is a good chance the news has caught your attention. A series of ...

Kenvue (KVUE) stock is in focus as the company prepares a strong defense as an HHS report may link its Tylenol (acetaminophen ...

Study reveals gaps in cough management in India, emphasizing need for scientific evaluation, rational prescribing, and ...

Research based on over 22 lakh patient records highlights high antibiotic use, poor categorisation of cough, and the need for ...

A recent study highlights improper categorization and treatment of cough in India. It emphasizes the overuse of antibiotics and fixed-dose combinations, urging a scientific approach to evaluation and ...